Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06788522 · ClinicalTrials.gov registry record · Phase 4
The Effects of Orexin Antagonism on Fear Extinction in PTSD
A Phase 4 study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- Phase 4
- Development phase
- 40,120
- Enrollment target
NCT06788522: Clinical Trial Phase 4 study, sponsored by VA Office of Research and Development.
NCT06788522 is a Phase 4 study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 40,120 participants, above the 514-participant average among 9,235 other Phase 4 trials with a reported enrollment target (7705% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06788522, a Phase 4 study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 40,120 participants
- Enrollment target
Study Summary
PTSD affects approximately 22% of Veterans who have served in Iraq and Afghanistan. Symptoms of PTSD may include re-experiencing, avoidance of trauma reminders, negative thoughts or feelings, and hyperarousal, such as increased startle reactivity and disturbed sleep. Treatments for PTSD are based on fear extinction principles in which individuals are repeatedly exposed a feared cue in the absence of danger, resulting in diminishing physiological reactions, a process believed to underlie recovery from PTSD. Studies suggest that orexin, a wake-promoting neuropeptide, may enhance fear extinction. This study will examine whether suvorexant, a selective orexin-receptor antagonist, will enhance fear extinction in Veterans with PTSD and insomnia. Finding a role for orexins in fear extinction will support the rationale for its further evaluation in the treatment of PTSD. Suvorexant is an accessible, safe medication that has been well-established in treating insomnia. It has outstanding promise for treating common and distressing symptoms in Veterans with PTSD.
Primary Outcome
Goal of enrolling 40 individuals to achieve a total of 30 completers by the end of month 23.
Interventions
- DRUG Placebo
- DRUG Suvorexant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40,120 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2032-06-30 |
| Phase | Phase 4 |
What is known before NCT06788522 opens enrollment
NCT06788522 is an interventional study that assigns participants to a tested intervention. Its 40,120 participants enrollment target places it among the larger protocols in the corpus, above the 514-participant average among 9,235 other Phase 4 trials with a reported enrollment target (7705% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06788522 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06788522 about?
NCT06788522 is a clinical study titled "The Effects of Orexin Antagonism on Fear Extinction in PTSD". PTSD affects approximately 22% of Veterans who have served in Iraq and Afghanistan. Symptoms of PTSD may include re-experiencing, avoidance of trauma reminders, negative thoughts or feelings, and hyperarousal, such as increased startle reactivity and disturbed sleep. Treatments for PTSD are based on...
What is the current status of trial NCT06788522?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 40,120 participants. The study started on 2026-06-01. Estimated completion is 2032-06-30.
What interventions are being tested in trial NCT06788522?
The interventions under investigation include: Placebo (DRUG), Suvorexant (DRUG).
Who is sponsoring clinical trial NCT06788522?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06788522's enrollment target sits among peer trials
40,120 4th of 2000 higher than 1,997 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
- NCT04994756 · 40,000 participants
Stroke Thrombectomy and Aneurysm Registry
- NCT06768814 · 40,000 participants · NA
Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data
- NCT07109427 · 40,000 participants · NA
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI